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Abstract
Background: Significant progress in treatment of metastatic castration resistant prostate cancer (mCRPC) has been
made. Biomarkers to tailor therapy are scarce. To facilitate decision-making we evaluated dynamic changes of
alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and prostate specific antigen (PSA) under therapy with
Abiraterone.
Methods: Men with bone mCRPC (bmCRPC) on Abiraterone 12/2009-01/2014 were analyzed. Dynamic ALP-, LDH-
and PSA-changes were analyzed as predictors of best clinical benefit and overall survival (OS) with logistic-
regression, Cox-regression and Kaplan-Meier-analysis.
Results: Thirty-nine pre- and 45 post-chemotherapy patients with a median follow up of 14.0 months were analyzed.
ALP-Bouncing can be observed very early during therapy with Abiraterone. ALP-Bouncing is defined as rapidly rising
ALP-levels independent of baseline ALP during the first 2–4 weeks of Abiraterone-therapy with subsequent equally
marked decline to pretreatment levels or better within 8 weeks of therapy, preceding potentially delayed PSA-decline.
In univariate analysis failure of PSA-reduction ≥50 % and failure of ALP-Bouncing were the strongest predictors of
progressive disease (p = 0.003 and 0.021). Rising ALP at 12 weeks, no PSA-reduction ≥50 % and no ALP-Bouncing were
strongest predictors of poor OS, (all p < 0.001). Kaplan-Meier-analysis showed worse OS for rising ALP at 12 weeks, no
PSA-reduction ≥50 % and no ALP-Bouncing (p < 0.001). In subgroup-analysis of oligosymptomatic patients all
parameters remained significant predictors of poor OS, with no PSA-reduction ≥50 % and rising ALP at 12 weeks being
the strongest (p < 0.001). In multivariate analysis PSA-reduction ≥50 % remained an independent predictor of OS for
the whole cohort and for the oligosymptomatic subgroup (both p = 0.014). No patient with ALP-Bouncing had PD for
best clinical benefit. Patients with rising ALP at 12 weeks had no further benefit of Abiraterone.
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Conclusions: Dynamic changes of ALP, LDH and PSA during Abiraterone-therapy are associated with best clinical
benefit and OS in bmCRPC. ALP-Bouncing occurring earlier than PSA-changes as well as prior to equivocal imaging
results and rising ALP at 12 weeks under Abiraterone may help to decide whether to discontinue Abiraterone. An
external validation of these findings on a prospective cohort is planned.
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Background
During the past 10 years significant progress has been
achieved in treatment of metastatic castration resistant
prostate cancer (mCRPC). Several drugs with potential
to extend overall survival (OS) have been approved,
some of which harbor fairly little toxicity [1–9].
Amongst these Abiraterone acetate is available in pre-
and post-chemotherapy setting and has become a
broadly accepted standard of care. A major challenge for
clinicians, researchers and indirectly for reimbursers is the
measurement of treatment success due to lack of reliable,
validated and easily available biomarkers for predicting
outcomes and clinically relevant endpoints for modern
therapies. Therefore, the decision for or against a drug out
of an increasing repertory, therapy monitoring while on
the drug and decision-making on continuation of therapy
is delicate.
Several biomarkers have previously been described in-
cluding prostate specific antigen (PSA), circulating
tumor cells (CTC), alkaline phosphatase (ALP) and lac-
tate dehydrogenase (LDH) [10–18]. However, these
markers are not always straightforward or interpretable
beyond doubt. PSA can rise during the first 3–6 months
of therapy before declining [10, 18, 19]. Baseline CTC-
enumeration and changes during therapy have been
shown to be surrogate for survival endpoints [15], but
lack broad availability and display limited accuracy with
currently available kits [11, 16]. LDH is used in a multi-
tude of cancers and baseline-level has been found to be
surrogate for OS before Abiraterone-therapy [15] but is
relatively unspecific. ALP has prognostic potential in
mCRPC treated with Docetaxel and Radium-223 [12, 14,
17] but changes during therapy have not yet been evalu-
ated in depth. An interesting phenomenon, which we
call “ALP-Bouncing”, seems to happen with some pa-
tients at a very early stage of antihormonal therapy in
bone mCRPC (bmCRPC) followed by sometimes dra-
matic and prolonged response. In these patients ALP
may rise to extreme levels during the first 2–4 weeks be-
fore eventually declining to pre-treatment levels or bet-
ter. This ALP-bouncing does not last longer than
8 weeks after initiation of therapy and usually precedes
PSA decline. However, this event does not occur in a
uniform way. The phenomenon was first described in
1945 after bilateral orchiectomy of a bone-metastatic
prostate cancer patient [13]. To our knowledge, the rele-
vance for therapy monitoring has never been investi-
gated before.
Altogether biomarkers in mCRPC are yet to be estab-
lished in many ways to help in decision-making and to
guide treatment algorithms. In this study we aimed to
investigate the possible surrogate function of ALP along-
side PSA and LDH in bmCRPC-patients.
Methods
Patients
After IRB-approval (Muenster University Medical Faculty),
all patients with mCRPC presenting at the Department of
Urology, Muenster University Medical Center between 12/
2009-01/2014 who received Abiraterone were retrospectively
reviewed to evaluate possible biomarkers and their dynamic
changes as surrogates for best clinical benefit and OS during
very early Abiraterone-therapy. All patients gave written
informed consent before participating (Additional file 1).
The patients presented with confirmed mCRPC (defined
by PCWG2-criteria [20]) in pre- or post-chemotherapy
setting suitable for Abiraterone-treatment. For the pre-
chemotherapy subpopulation patients had to be asymp-
tomatic or oligo-symptomatic with no use of opiates and a
pain level of ≤3 out of 10 on the numeric-rating-scale. For
the post-chemotherapy subpopulation, progressive disease
(PD) had to be evident either on or after chemotherapy. A
total of 96 patients presented during the reviewed time
frame. Three of these patients had received prior Enzalu-
tamide. One patient with a secondary malignancy and one
beforehand treated with Ketokonazole were excluded
from final analyses. Since ALP is a bone metastasis
dependent marker, patients without bone metastases were
excluded from final analyses, resulting in 84 evaluable pa-
tients, 39 in pre- and 45 in post-chemotherapy setting. All
patients in the analysis were either on a stable dose of an
antiresorptive agent (i.e. Zoledronic acid or Denosumab)
at least 3 months prior to start of Abiraterone and during
the whole treatment phase or did not receive antiresorp-
tive medication at all. Four (4.7 %) patients were treated
within the pre-chemotherapy registration trial for abirater-
one (COU-AA-302) [4]. These patients were systematic-
ally followed up with 12-weekly imaging even when no
PD was suspected. All other patients were treated within
standard of care.
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Patients presented the day before start of Abiraterone-
therapy to have blood drawn for baseline analysis, two and
4 weeks after initiation of therapy and 4 weekly thereafter.
LDH-, ALP- and PSA-levels were immediately measured
in the serum samples within routine analysis. Dynamic
changes of LDH, ALP and PSA were documented.
ALP-Bouncing was defined as rapid elevation above the
upper normal limit (UNL) during the first 2–8 weeks of
Abiraterone-treatment with an equally marked decline to
pretreatment levels or better within the same interval.
CT-, MRI- or Cholin-PET-CT-scans of thorax, abdomen
and pelvis were used for the evaluation of soft tissue
metastases. Bone scans were done to acquire additional
information on baseline bone metastases. Imaging was re-
peated during Abiraterone-therapy when clinically indi-
cated and not in routine fashion. PD was defined by
RECIST 1.1 criteria [21] for cross sectional imaging and
by PCWG2 criteria for bone scans [20].
A physician (MB) with large expertise in the treatment
of mCRPC assessed the current response status i.e.
complete remission (CR), partial remission (PR), stable
disease (SD) or PD at each visit. For defining disease
progression, deterioration of general condition, worsen-
ing of pain and worsening laboratory constellations as
well as imaging were taken into account. Patients were
subdivided into two groups according to ALP-status
(group-1: no ALP-bouncing, group-2: ALP-bouncing).
The study was performed according to the STROBE-criteria
(Additional file 2: STROBE statement).
Statistical methods
The descriptive statistics are reported as the medians with
95 % confidence intervals (CI) or interquartile range (IQR)
for continuous variables and as populations and frequen-
cies for categorical variables. The χ2-test, Fisher’s exact-
test, t-test or Mann–Whitney U-test were performed to
determine the significance of the differences between cat-
egorical and continuous variables, respectively. Survival
analysis was performed with Kaplan-Meier-analysis [22].
Univariate and multivariate analysis of the different bio-
markers were done with binary logistic-regression and
Cox-regression-models. For all patients for whom time-
dependent variables were used within the Cox-regression-
models the follow-up period was at least 12 weeks long.
All reported p-values are two-sided and statistical signifi-
cance was assumed as p ≤ 0.05. SPSS-Statistics V.22 (IBM
Inc., Armonk, NY) was used for statistical assessment.
Results
Patient characteristics
The final cohort consisted of 39 men in pre- and 45 in
post-chemotherapy setting. Median follow-up was 14.0
(IQR 10.0–18.0) months for the patients alive at time of
analysis. The median time on Abiraterone therapy was
10.0 months (IQR 5.0–14.0) with 18 (21 %) patients with
ongoing therapy at the time of analysis. For one patient
the Abiraterone dose had to be halved due to elevation of
transaminases after 4 weeks of therapy. For all other pa-
tients no dose modifications were necessary. Descriptive
characteristics of the cohort are given in Table 1. The me-
dian age of the patients was 69 years (IQR: 62.3–76.0).
Visceral metastases were present in 20 % at the beginning
of Abiraterone. Unfavorable Gleason-Score of ≥8 at initial
diagnosis was found in 60.8 %. Median baseline PSA-,
ALP- and LDH-levels were 174 ng/ml, 155 U/l and 287
U/l, respectively.
ALP-Bouncing is defined as rapidly rising ALP-levels in-
dependent of baseline ALP-level during the first 2–4 weeks
of Abiratereone-therapy with subsequent equally marked
decline to pretreatment levels or better within 8 weeks of
therapy, preceding potentially delayed PSA-changes (Fig. 1).
Patients with ALP-Bouncing had significantly less baseline
visceral metastases (8.8 vs. 28.0 %, p = 0.032). Those with
ALP-Bouncing had a higher percentage of CR, PR
and SD (100 % vs. 76 %, p < 0.001) and LDH
normalization (59.1 % vs. 27.0 %, p = 0.015) (Table 1).
In the subpopulation of patients with ALP-Bouncing
68 % had a PSA-decline of ≥50 % and 24 % a decline
of ≥90 %. In patients without ALP-Bouncing 30 % showed
a PSA-decline of ≥50 % and only 5 % declined by ≥90 %
(all p < 0.001) (Fig. 2).
Antiresorptive therapy (Zoledronic acid or Denosumab)
were well balanced in both the ALP-Bouncing- and non
ALP-Bouncing-subgroups (70.6 and 64.0 %) (Table 1).
Value of ALP, PSA and LDH as prognostic markers of
clinical benefit
In univariate analyses of parameters for best clinical
benefit (defined as PD vs. CR/PR/SD) presence of vis-
ceral metastases, no ALP-Bouncing, no PSA-reduction
of ≥50 % and rising ALP at 12 weeks of Abiraterone-
therapy showed a statistically significant higher risk of
PD (Table 2). No PSA-reduction of ≥50 % and no
ALP-Bouncing were the strongest predictors of PD
(Odds ratio: 24.9, 95%CI: 3.1–202.1, p = 0.003 and
11.6, 95%CI: 1.4–93.5; p = 0.021, respectively)).
Results of univariate analyses for OS are displayed in
Table 3 and in Additional file 1: Table S1. No ALP-
Bounce, worse eastern cooperative oncology group
performance status (ECOG) (2 vs. 0–1), no PSA-reduction
of ≥50 % or ≥90 %, rising ALP at 12 weeks of Abiraterone-
therapy, baseline-LDH >UNL and failure of LDH-
normalization under Abiraterone-therapy were significant
predictors of worse OS, with rising ALP at 12 weeks of
Abiraterone-therapy, no PSA-reduction of ≥50 % and
no ALP-Bouncing being the strongest predictors
(Hazard-ratio (HR): 4.9, 95%CI: 2.7–8.9, 4.2, 95%CI:
2.3–7.6 and 3.1, 95%CI: 1.7–5.7; all p < 0.001,
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respectively). In subgroup analysis of patients with asymp-
tomatic or oligosymptomatic bmCRPC (ECOG 0–1)
(results are given in Additional file 1: Table S1) all of these
parameters remained significant predictors of poor
OS. No PSA-reduction of ≥50 % and rising ALP at
12 weeks showed the highest level of significance
(HR: 5.7, 95%CI: 2.8–11.7 and 4.3, 95%CI: 2.1–8.7;
both p < 0.001).
Kaplan-Meier analyses for OS are shown in Fig. 3. All
relevant markers identified in univariate analyses also
showed significantly worse OS in Kaplan-Meier analyses,
with rising ALP at 12 weeks of Abiraterone-therapy (me-
dian OS: 8 months, 95%CI: 5.9–10.0), no PSA-reduction
of ≥50 % (median OS: 9 months, 95%CI: 6.7–11.4) and no
ALP-Bouncing (median OS: 10 months, 95%CI: 6.2–13.8)
being the strongest predictors (all p < 0.001).
Multivariate evaluation of predictive biomarkers
In multivariate analyses for OS only no PSA-
reduction of ≥50 % remained an independent signifi-
cant predictor of OS (HR: 2.8, 95%CI: 1.2–6.3; p =
0.016) after adjusting for ALP-Bouncing, rising ALP
at 12 weeks of Abiraterone-therapy, ECOG and LDH-
normalization (Table 3). In multivariate analyses of
the subgroup of asymptomatic and oligosymptomatic
bmCRPC-patients no PSA decline of ≥50 % continued
to be a significant predictor of poor OS (HR: 4.1,
95%CI: 1.3–12.9; p = 0.018) after adjusting for ALP-
Bouncing, rising ALP at 12 weeks of Abiraterone-
therapy and LDH-normalization (Additional file 1:
Table S1).
Only 8 of 27 (30 %) patients with rising ALP at
12 weeks of Abiraterone without prior ALP-Bouncing
Table 1 Characteristics of patients with bmCRPC on AA with or without ALP-Bouncing
Variable all no ALP-Bouncing ALP-Bouncing p
Patients [n], (%) 84 50 (60) 34 (40) -
Age, median [years] (IQR) 69.0 (62.3–76.0) 68.0 (61.0–75.5) 70.5 (66.5–76.0) 0.304
Lnn. Metastases [n] (%) 45 (53.6) 27 (54.0) 18 (52.9) 0.924
Visceral Metastases [n] (%) 17 (20.2) 14 (28.0) 3 (8.8) 0.032
Pre CTX [n] (%) 39 (46.4) 24 (48.0) 15 (44.1) 0.726
Post CTX [n] (%) 45 (53.6) 26 (52.0) 19 (55.9) 0.726
Patients died [n] (%) 53 (63.1) 39 (78.0) 14 (41.2) -
Antiresorptive therapy [n] (%) 56 (66.7) 32 (64.0) 24 (70.6) 0.530
Zoledronic acid [n] (%) 42 (50.0) 24 (48.0) 18 (52.9) 0.821
Denosumab [n] (%) 14 (16.7) 8 (16.0) 6 (17.6)
Best clinical outcome [n] (%)
CR 1 (1.2) 0 (0) 1 (2.9)
<0.001
PR 51 (60.7) 22 (44.0) 29 (85.3)
SD 20 (23.8) 16 (32.0) 4 (11.8)
PD 12 (14.3) 12 (24.0) 0 (0)
ECOG (all) [n] (%)
0 12 (14.3) 7 (14.0) 5 (14.7) 0.351
1 53 (63.1) 29 (58.0) 24 (70.6)
2 29 (22.6) 14 (28.0) 5 (14.7)
GS≥ 8 [n] (%)a 45 (60.8) 29 (67.4) 16 (51.6) 0.169
PSA red. ≥ 50 % [n] (%) 47 (56.0) 19 (38.0) 28 (82.4) <0.001
PSA red. ≥ 90 % [n] (%) 22 (26.2) 6 (12.0) 16 (47.1) <0.001
Median PSA Baseline [ng/ml] (IQR) 174 (55–500) 105 (47–457) 151 (54–477) 0.824
Median LDH Baseline [U/l] (IQR) 287 (223–422) 290 (228–565) 252 (218–327) 0.125
Median ALP Baseline [U/l] (IQR) 155 (102–355) 171 (96–381) 154 (114–273) 0.895
ALP rising at 12 w AA [n] (%) 27 (33.3) 27 (57.4) 0 (0) -
LDH BL > UNL [n] (%) 58 (71.6) 37 (77.1) 21 (63.6) 0.187
LDH normalization [n] (%) 23 (39.0) 10 (27.0) 13 (59.1) 0.015
aPatients for whom the GS-information was not available were excluded from GS analysis (n = 10)
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had PR, 8 (30 %) had SD and 11 (40 %) had PD as best
clinical benefit. In comparison, no patient with ALP-
Bouncing had PD as best clinical benefit.
Discussion
There are few biomarkers in mCRPC helping physicians
in tailoring therapy. The utility of biomarkers depends
on the clinical situation in which they are applied.
Especially in bmCRPC (80–90 % of all mCRPC-
patients) early “bone-flare” in imaging is common under
hormonal drugs like Abiraterone. This dilemma leads to
many cases of misinterpretation, as apparent progression
on imaging might be discordant with patients’ reports
and clinical observation. This difficulty holds especially
true in asymptomatic or oligo-symptomatic patients with
no additional clinical information by change of symp-
toms [23].
PSA is most commonly used for therapy monitoring.
However it may rise under therapy before declining.
This PSA-flare can last as long as three or sometimes 6
months and mimic PD [19]. This may challenge the clin-
ician whether to discontinue the drug, especially in pa-
tients with asymptomatic or oligosymptomatic disease




































Fig. 1 Rising PSA is a common phenomenon during the first
12 weeks of Abiraterone therapy followed by either continued rising
PSA representing true disease progression or delayed PSA-decline
representing response to therapy. ALP-Bouncing, occurring in 40 %
of the studied patients with bmCRPC happens at a very early stage
of antihormonal therapy and is defined as rapidly rising ALP-levels
independent of baseline-ALP during the first 2–4 weeks of therapy
with subsequent, equally marked, decline to pretreatment levels or
better no later than 8 weeks after initiation of therapy. This can precede
potentially delayed PSA-declines. This phenomenon does not occur in a
uniform way
Fig. 2 In the subpopulation of patients with ALP-Bouncing 68 % of patients had a PSA-decline of ≥50 % and 24 % even had a decline of ≥90 %.
In patients without ALP-Bouncing only 30 % showed a PSA-decline of ≥50 % and only 5 % declined by ≥90 % (all p < 0.001)
Table 2 Univariate analyses of biomarkers for progressive
disease as best clinical benefit in bmCRPC on Abiraterone-
therapy
Variable OR (95 % CI) p
PSA decline≥ 50 % no vs. yes 24.9 (3.1–202.1) 0.003
No-Bouncing vs. ALP-Bouncing 11.6 (1.4–93.5) 0.021
ALP rising after 12 w yes vs. no 6.3 (1.7–22.8) 0.006
Visceral Mets. yes vs. no 4.0 (1.2–13.9) 0.028
ECOG 2 vs. 0–1 3.3 (1.0–11.1) 0.055
LDH normalization no vs. yes 3.0 (0.6–15.6) 0.192
LDH BL > UNL yes vs. no 2.2 (0.4–10.9) 0.338
ALP BL > UNL yes vs. no 1.3 (0.4–4.3) 0.698
AA post-CTX vs. pre-CTX 1.2 (0.4–3.7) 0.769
Lnn. Mets. yes vs. no 1.2 (0.4–3.8) 0.769
GS≥ 8 vs. GS < 8 1.2 (0.3–4.4) 0.835
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therapy or even circulatory release of PSA due to tumor
cell death and therefore harbor good prognosis [10]. The
PCWG2 therefore recommends not stopping an individ-
ual therapy on the basis of early rising PSA alone. How-
ever, PCWG2 advises to document the efficacy of an
individual therapy in clinical trials by determining the
relative amount of patients with a PSA-decline of ≥50 %
at 12 weeks [24]. In the registration trials for Abirater-
one (COU-AA-302 and COU-AA-301) [4, 25], PSA-
decline was no sole marker defining progressive disease.
However, outside of clinical trial scenarios with the given
problems of regularly delayed confirmation of dynamics
of bone metastases on imaging, PSA is the only informa-
tion available to the physicians to make decisions.
CTCs have been found to show changes earlier than PSA
and no “flare” phenomenon has been reported. Dynamic
changes in CTC-enumeration in early Abiraterone-therapy
can serve as surrogate for response to treatment with po-
tential translation into survival outcomes [15]. Early CTC-
changes could help in steering therapy foremost in men
with no or little symptoms. But CTCs have several disad-
vantages including high costs and limited routine availabil-
ity to this point. Additionally CTCs measured with
currently available assays display limited sensitivity [11, 16].
Table 3 Univariate and multivariate analyses of significant biomarkers for OS in 84 bmCRPC-patients under Abiraterone-therapy
Univariate analysis Multivariate analysis
Variable HR (95 % CI) p Variable HR (95 % CI) p
PSA decline≥ 50 % no vs. yes 4.2 (2.3–7.6) <0.001 PSA decline≥ 50 % no vs. yes 2.8 (1.2–6.3) 0.016
No-Bouncing vs. ALP-Bouncing 3.1 (1.7–5.7) <0.001 No-Bouncing vs. ALP-Bouncing 2.0 (0.7–5.7) 0.181
ALP rising after 12 w yes vs. no 4.9 (2.7–8.9) <0.001 ALP rising after 12 w yes vs. no 1.5 (0.6–3.9) 0.412
ECOG 2 vs. 0–1 2.7 (1.4–5.0) 0.002 ECOG 2 vs. 0–1 1.4 (0.6–3.1) 0.387
PSA decline≥ 90 % no vs. yes 3.0 (1.5–6.1) 0.003 - - -
LDH normalization no vs. yes 2.6 (1.3–5.0) 0.005 LDH normalization no vs. yes 1.8 (0.8–3.9) 0.143
LDH BL > UNL yes vs. no 2.1 (1.0–4.3) 0.048 LDH BL > UNL yes vs. no 1.2 (0.2–7.1) 0.826
Visceral Mets. yes vs. no 1.8 (0.9–3.3) 0.076 Visceral Mets. yes vs. no 1.0 (0.5–2.2) 0.076
AA post-CTX vs. pre-CTX 1.5 (0.8–2.7) 0.175 - - -
ALP BL > UNL yes vs. no 1.4 (0.8–2.5) 0.199 - - -
GS≥ 8 vs. GS < 8 1.3 (0.7–2.4) 0.365 - - -
Lnn. Mets. yes vs. no 0.9 (0.6–1.6) 0.804 - - -
Fig. 3 The Kaplan-Meier analysis showed significantly worse OS for no ALP-Bouncing (a) and no PSA-decline of ≥50 % (b). No ALP-Bouncing and
no PSA-decline of ≥50 % were the strongest predictors of poor overall survival on Abiraterone therapy
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LDH is an unspecific biomarker in many tumor-types
as well as mCRPC. Elevated or inclining LDH reflects
higher tumor burden and/or high proliferation activity
[26]. In the registration trial of Abiraterone for the post-
chemotherapy setting baseline-LDH >UNL was prognos-
tic for OS, therefore, a combination of LDH and CTCs
has been proposed [15]. Rising LDH-levels under therapy
indicate poor prognosis [27], and a normalization of a
beforehand-elevated LDH might be predictive of response
as well.
ALP has been shown to be prognostic in patients
with mCRPC treated with Docetaxel and Radium-223
[12, 14, 17]. Thus serial measurements of ALP to
discern dynamic changes may provide prognostic in-
formation in Abiraterone and other hormonal manip-
ulations. To our knowledge this has not been studied
before in relation to a specific antihormonal therapy.
Especially ALP-Bouncing during very early therapy as
described in this manuscript has not been reported
previously.
With Abiraterone in the current treatment landscape
being mostly used in the pre-chemotherapy setting in
asymptomatic or oligosymptomatic patients the absence
of symptoms brings along the physicians dilemma of not
being able to determine the state of clinical response
from the course of patients’ wellbeing alone. Lack of
clinical symptoms with rising PSA can only be dealt with
by imaging. Imaging itself, typically performed at
12 weeks of treatment, brings along a high rate of bone
flares suggesting disease progression [23], leaving the
physician in the dilemma of not knowing if continuation
of a drug will be beneficial for the patient. Until now it
is state of the art not to consider a sole PSA-rise a criter-
ion of progress [20] and to continue medication until
clinical progression occurs or repeated imaging several
months later confirms progression. This approach har-
bors the possibility of unwillingly missing progression
and continuing an inefficacious therapy. The individual
patient might even lose time in which he could have
been treated with other possibly life-prolonging drugs.
This procrastination of switching therapy may lead to
worsening of physical reserves for e.g. chemotherapy
and render it in some cases impossible due to physical
deterioration. The adherence to a non-efficacious ther-
apy could also increase the preexisting financial burden
for reimbursers.
Future biomarkers might help to improve customized
therapy approaches in a growing landscape of treatment
options. One possible marker was recently reported with
the splice variant AR-V7 as a marker to predict response
to subsequent therapy with Enzalutamide or Abiraterone
before start of the drug [28]. A potential role of AR-V7
or other splice-variants in guiding Abiraterone-therapy
remains to be established.
This study is limited by deficiencies inherent to a
retrospective review. The cohort of 84 bmCRPC-patients
is a very large number of consecutive patients for a single
center study in this setting, however when subgrouping
was performed the group size became relatively small.
Also, patients in pre- and post-chemotherapy setting were
grouped together, due to cohort size. In the COU-AA-
302- and −301-trials radiographic progression-free sur-
vival was a primary endpoint [4, 25]. Per protocol up to 2
new bone metastases in the first bone scan after 12 weeks
of abiraterone-therapy were primarily considered a poten-
tial bone flare and had to be confirmed with at least 2 add-
itional bone metastases in a subsequent bone scan 8–12
weeks later. In our study systematic imaging was not per-
formed 12-weekly. When PD was suspected imaging was
performed for confirmation in most of the cases except in
patients with unequivocal progression. Therefore, radio-
graphic progression-free survival was not assessed. In our
opinion this does not impair the results of our trial since
very early ALP-dynamics are not meant to be parameters
to define progression at a specified point in time but to
predict the general outcome of Abiraterone-therapy much
earlier than current imaging could.
Since antiresorptive therapy was well balanced be-
tween Zoledronic acid and Denosumab, when applied at
all, and stable antiresorptive therapy had to be estab-
lished within all patients analyzed, our results are not
affected by these drugs with potential impact on ALP-
levels.
Our study is the first to address dynamic changes of
the easily available biomarkers ALP, LDH and PSA dur-
ing very early Abiraterone-therapy in bmCRPC. Our re-
sults underline the importance of PSA-decline of ≥ 50 %
as an important surrogate for best clinical benefit and
OS as suggested by the PCWG2 [20]. Additionally, the
presence of ALP-Bouncing in the first 2–8 weeks of
therapy is a strong predictor for subsequent long lasting
clinical response. In comparison to PSA with a relevant
number of flares during the first 3–6 months of therapy,
ALP gives earlier and straightforward information on the
future course of disease in an important subset of pa-
tients. However, in our study ALP-Bouncing was not an
independent predictor for OS. The reason for this is that
ALP-Bouncing and PSA-decline of ≥ 50 % are not dis-
crepant in a relevant number of cases, so for the given
number of patients there are not enough differences to
show significance in multivariate analysis for both vari-
ables. Nevertheless, our findings are very relevant for pa-
tients with non-concordant alterations. In our opinion, it
appears to be safe to continue with Abiraterone when-
ever ALP-Bouncing has occurred even when PSA has
not declined by ≥50 %. All patients who had rising
ALP > UNL at 12 weeks of Abiraterone-therapy with no
prior ALP-Bouncing had a bad course of disease when
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continued on Abiraterone even with ECOG 0–1. There-
fore, from our perspective it might be equally reasonable
to stop Abiraterone treatment in this constellation in
carefully selected patients with bmCRPC. This could im-
prove current practice of having to wait for repeat bone
scans to confirm progression in asymptomatic or oligo-
symptomatic patients. However, prior to external valid-
ation of our findings PD should be proven by imaging
before discontinuation of therapy.
These findings should be confirmed in other popula-
tions, preferably in prospective trials or at least in post-
hoc analyses of large trial populations in which all these
parameters were regularly assessed (e.g. COU-AA-302).
A prospective validation is currently planned.
Despite these limitations the study is the first that re-
lates to very early changes of an easily available bio-
marker showing potential to aid physicians to tailor
therapy earlier than PSA and imaging in a difficult clin-
ical situation.
Conclusions
ALP-Bouncing is a promising biomarker which might
aid at a very early stage of Abiraterone-therapy to safely
continue or stop Abiraterone at 8–12 weeks in the de-
scribed constellations of asymptomatic or mildly symp-
tomatic patients with bmCRPC.
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